ArticleAesthetic surgery journal2025
Semaglutide and Postoperative Outcomes in Nondiabetic Patients Following Body Contouring Surgery.
Article in Aesthetic surgery journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies.Aesthetic plastic surgery · 2026Article
- Prehabilitation for Aesthetic Surgery: An Evidence-based Guide.Plastic and reconstructive surgery. Global open · 2026Article
- Perioperative GLP-1 Receptor Agonist Use and 30-Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study.World journal of surgery · 2026Article
- Psychosocial Outcomes and Aesthetic Expectations in Female Patients Undergoing Body Contouring After GLP-1-Induced Weight Loss: A Prospective Pilot Comparative Study with Post-Bariatric Patients.Aesthetic plastic surgery · 2026Article
- Impact of Preoperative Semaglutide Discontinuation Timing on Postoperative Outcomes in Aesthetic Abdominoplasty: A Retrospective Comparative Study.Aesthetic plastic surgery · 2026Article
- GLP-1 Receptor Agonists in Aesthetic Surgery: A Narrative Review on Perioperative Safety, Sarcopenic Morphologies, and Adapted Body Contouring Strategies.Aesthetic plastic surgery · 2026Review
- Perioperative glucagon-like peptide-1 receptor agonist use and surgical outcomes in patients with morbid obesity (BMI > 35) undergoing robotic urologic surgery: A propensity score-matched analysis.Journal of robotic surgery · 2026Article
- The Influence of Glucagon-like Peptide-1 Receptor Agonists on Outcomes Following Trigger Finger Release.Journal of hand surgery global online · 2026Article
- Nonsurgical Aesthetic Treatment of the Face and Neck in GLP-1 Receptor Agonist Weight Loss Patients: Experience-Based Considerations.Aesthetic surgery journal. Open forum · 2026Article
- "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.Aesthetic surgery journal. Open forum · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSemaglutide is a medication for weight loss in obese patients. Recently, many plastic surgeons have recommended semaglutide following bariatric surgery to increase weight loss. However, postoperative complications such as wound dehiscence, delayed healing, and infection pose significant risks.
objectivesIn this study we aimed to examine the relationship between preoperative semaglutide and postoperative complications in nondiabetic obese patients undergoing body contouring surgery. We hypothesized that semaglutide would increase the risk of postoperative complications.
methodsIn this retrospective cohort study we utilized the TriNetX Research database. Nondiabetic patients who underwent body contouring surgery between 2021 and 2024 after bariatric procedures were included. Patients were divided into 2 cohorts: Cohort A (4215 patients), which received semaglutide for ≥6 months before surgery, and Cohort B (104,927 patients), without semaglutide. Propensity score matching was employed to create comparable cohorts based on age, gender, race, and BMI. The primary outcomes included postoperative complications within 30 days of surgery.
resultsSignificant differences were found between the cohorts. Semaglutide patients had higher rates of wound dehiscence (5.19% vs 2.78%, P < .0001); delayed wound healing (2.58% vs 1.21%, P < .0001); surgical site infections (5.37% vs 2.87%, P < .0001); nausea, vomiting, and diarrhea (11.27% vs 5.34%, P < .0001); hypertrophic scar formation (5.53% vs 3.86%, P = .0011); and surgical site pain (6.05% vs 3.29%, P < .0001).
conclusionsPreoperative semaglutide in nondiabetic patients undergoing body contouring surgery following bariatric procedures is associated with higher rates of adverse postoperative outcomes. These findings highlight the need for enhanced preoperative counseling and surgical planning to minimize risks and improve patient outcomes. LEVEL OF EVIDENCE: 3 (THERAPEUTIC):
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.